Integra LifeSciences Holdings Corporation

NYSE
IART
Stock
Yield per half year: -51.65%
Dividend yield: 0%
Sector: Healthcare

Company Analysis Integra LifeSciences Holdings Corporation

Download the report: word Word pdf PDF

1. Summary

Advantages

  • The company's current efficiency (ROE=-0.4433%) is higher than the sector average (ROE=-83.32%)

Disadvantages

  • Price (12.6 $) is higher than fair price (0.5879 $)
  • Dividends (0%) are below the sector average (1.28%).
  • The stock's return over the last year (-39.91%) is lower than the sector average (-18.83%).
  • Current debt level 49.15% has increased over 5 years from 40.81%.

Similar companies

Boston Scientific

Danaher Corporation

Allergan

Teleflex

2. Share price and performance

2.1. Share price

2.3. Market efficiency

Integra LifeSciences Holdings Corporation Healthcare Index
7 days -7.1% -14.1% -0.6%
90 days -34.4% -18% 5.7%
1 year -39.9% -18.8% 9%

IART vs Sector: Integra LifeSciences Holdings Corporation has significantly underperformed the "Healthcare" sector by -21.08% over the past year.

IART vs Market: Integra LifeSciences Holdings Corporation has significantly underperformed the market by -48.88% over the past year.

Stable price: IART is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.

Long period: IART with weekly volatility of -0.7675% over the past year.

3. Summary of the report

3.1. General

P/E: 52.88
P/S: 1.07

3.2. Revenue

EPS -0.0902
ROE -0.4433%
ROA -0.1776%
ROIC 0%
Ebitda margin 12%

4. Fundamental Analysis

4.1. Stock price and price forecast

The fair price is calculated taking into account the Central Bank refinancing rate and earnings per share (EPS)

Above fair price: The current price (12.6 $) is higher than the fair price (0.5879 $).

Price is higher than fair: The current price (12.6 $) is 95.3% higher than the fair price.

4.2. P/E

P/E vs Sector: The company's P/E (52.88) is higher than that of the sector as a whole (52.65).

P/E vs Market: The company's P/E (52.88) is lower than that of the market as a whole (61.83).

4.2.1 P/E Similar companies

4.3. P/BV

P/BV vs Sector: The company's P/BV (1.12) is lower than that of the sector as a whole (10.86).

P/BV vs Market: The company's P/BV (1.12) is lower than that of the market as a whole (20.82).

4.3.1 P/BV Similar companies

4.4. P/S

P/S vs Sector: The company's P/S indicator (1.07) is lower than that of the sector as a whole (4.03).

P/S vs Market: The company's P/S indicator (1.07) is lower than that of the market as a whole (16).

4.4.1 P/S Similar companies

4.5. EV/Ebitda

EV/Ebitda vs Sector: The company's EV/Ebitda (17.95) is higher than that of the sector as a whole (16.78).

EV/Ebitda vs Market: The company's EV/Ebitda (17.95) is lower than that of the market as a whole (27.04).

5. Profitability

5.1. Profitability and revenue

5.2. Earnings per share - EPS

5.3. Past profitability Net Income

Yield Trend: Negative and has fallen by -21.04% over the last 5 years.

Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-21.04%).

Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-8.87%).

5.4. ROE

ROE vs Sector: The company's ROE (-0.4433%) is higher than that of the sector as a whole (-83.32%).

ROE vs Market: The company's ROE (-0.4433%) is lower than that of the market as a whole (43%).

5.5. ROA

ROA vs Sector: The company's ROA (-0.1776%) is lower than that of the sector as a whole (6.43%).

ROA vs Market: The company's ROA (-0.1776%) is lower than that of the market as a whole (23.28%).

5.6. ROIC

ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (15.68%).

ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (9.2%).

6. Finance

6.1. Assets and debt

Debt level: (49.15%) is quite low in relation to assets.

Increasing debt: over 5 years, the debt has increased from 40.81% to 49.15%.

Excess of debt: The debt is not covered by net income, percentage -28579.54%.

6.2. Profit growth and share price

7. Dividends

7.1. Dividend yield vs Market

Low yield: The dividend yield of the company 0% is below the average for the sector '1.28%.

7.2. Stability and increase in payments

Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.5.

Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 1 year.

7.3. Payout percentage

Dividend Coverage: Current payments from income (137.64%) are at an uncomfortable level.

8. Insider trades

8.1. Insider trading

Insider Buying Exceeds insider sales by 100% over the last 3 months.

8.2. Latest transactions

Pay for your subscription

More functionality and data for company and portfolio analysis is available by subscription

9. Stocks forum Integra LifeSciences Holdings Corporation

9.3. Comments